Navigation Links
Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma

ng resistance mediated by Mcl-1 also reveals the breadth of the compound's therapeutic potential. These findings suggest that Gemin X's obatoclax (GX15-070) in combination with bortezomib may prove to be an attractive new approach in the treatment of MCL, and further support our recent initiation of this combination in a Phase 1b trial in MCL."

Gemin X is currently conducting several clinical trials of obatoclax (GX15-070) in multiple cancer types as a combination therapy and as a single agent. In addition to the Phase 1b trial in MCL, Gemin X recently initiated a Phase 1/2 clinical trial in combination with docetaxel in patients with non-small cell lung cancer. Obatoclax (GX15-070) is also in Phase 2 clinical trials in patients with Hodgkin's Lymphoma, myelofibrosis with myeloid metaplasia, myelodysplastic syndrome, and follicular lymphoma both as single agent and in combination with rituximab. In multiple Phase 1 studies, obatoclax (GX15-070) was well-tolerated and resulted in clinical and biological activity.

About Mantle Cell Lymphoma (MCL)

Mantle cell lymphoma (MCL) belongs to a group of diseases known as non-Hodgkin's lymphomas, which are related cancers that affect the lymphatic system. Mantle cell lymphoma is an aggressive B-cell lymphoma that historically has been resistant to current standard chemotherapeutic approaches, making it a difficult cancer to treat. The median survival time is three years and the ten-year survival rate is only 5-10%.

Gemin X Biotechnologies Inc. specializes in the discovery and development of novel small molecule cancer therapeutics based on the regulation of apoptosis, the body's natural ability to destroy injured or damaged cells. Gemin X's lead product, obatoclax (GX15-070), is a small molecule, pan-inhibitor of Bcl-2 pro-survival proteins and is currently in Phase 2 clinical trials. Gemin X is also developing a small molecule that induces apoptosis in p53-defective cancers. Gemin X is privately hel
'"/>




Page: 1 2 3

Related medicine technology :

1. Gemin X Presents Positive Preclinical Data of GX15-070 in Infant ALL at AACR Meeting
2. Gemin X Announces Publication of Preclinical Data of GX15-070 in Multiple Myeloma in Blood
3. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
4. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:2/27/2015)... , Feb. 27, 2015 The role of ... decade but one thing hasn,t changed: face-to-face meetings are ... relationships with Key Opinion Leaders. Yet at ... most valuable type of interaction, field medical teams within ... KOL interactions. This is just one of the challenges ...
(Date:2/27/2015)...  Following a bipartisan vote in the House ... the Medicare DMEPOS Competitive Bidding Improvement Act of ... released a statement praising the Committee,s work and ... "Today,s mark-up of the Competitive Bidding ... Committee is a critical step forward for this ...
(Date:2/27/2015)... , Feb. 27, 2015 An aggressive campaign ... cut the rate of infection with a dangerous drug-resistant ... Clostridium difficile, or C.diff, is a bacterium ... inflammation of the colon. A recent article in the ... difficile Infection in the United States ...
Breaking Medicine Technology:Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3
... May 15, 2012 Millennium Surgical Corp. continues to ... activity increased in the third quarter of 2011 and ... of new clients for the first four months of ... FY2011. To accommodate additional clients and the increasing number ...
... -- Global Information Inc. is pleased to announce ... Contract Research Organizations Market to 2018 The ... 12% from 2009 to 2010 according to GBI Research,s ... to 2018 : Public-Private Partnerships to Strengthen Research Capacities ...
Cached Medicine Technology:Millennium Surgical Corp. Announces Sales Figures, Growth 2Contract Research Organizations Set to Experience Rapid Growth as Development Costs for New Drugs Continue to Rise 2
(Date:2/28/2015)... The Heart Fit Clinic started doing External ... machine. The Heart Fit Clinic is also selling the ... model. The goal is to scale the business to ... buy External Counterpulsation machines can be difficult ... this process and achieve the desired results. , ...
(Date:2/28/2015)... Indosoft Inc , developers of Q-Suite, a ... to announce the development of Q-Suite 5.9. Building off ... Q-Suite, this new version will include enhancements to existing ... to the leading edge call center software. General availability ... features to enhance security and protection. Administrators will be ...
(Date:2/28/2015)... St. Louis, MO (PRWEB) February 28, 2015 ... a leading provider of outsourced sales, marketing and ... announces their client, BIOTA Botanicals, is bringing its ... , Celebrated worldwide, BIOTA Botanicals’ products are specifically ... the herbal care experts, BIOTA is committed to ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 How ... Supportive? Strategic? , There are all kinds of ... To raise awareness of the advantages and applications ... PeopleKeys is launching a new product this spring ... better understand the connection between personality type, leadership, ...
(Date:2/28/2015)... 2015 Javon Bea Mercy Health ... Hospital as stroke capable by the State of Illinois, ... to Mercy Harvard Hospital. , The hospital was required ... ability to treat stroke according to national standards of ... stroke patients to bypass hospitals not designated as an ...
Breaking Medicine News(10 mins):Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2
... VAXINE Pty Ltd, a South Australian biotechnology company, has ... swine flu vaccine. , , ... administration to human subjects of a swine flu vaccine anywhere ... "The swine influenza vaccine we are testing, unlike old-fashioned egg-based ...
... HILLS, Mass., July 22 Joseph F. Finn, Jr., C.P.A. ... have been assigned to him for the benefit of EPIX,s ... and services focus on the discovery and development of novel ... in silico drug discovery platform. The company ...
... DOYLESTOWN, Pa., July 22 Quigley Pharma Inc., a wholly-owned ... www.quigleyco.com , today announced the ... compound QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. ... with the final and comprehensive conclusions revealing that (i) the ...
... , , , ... Inc. (OTC Bulletin Board: TCSR), which develops, manages and owns ... six-month extension of its construction/mini-perm loan with Trustmark National Bank. ... senior living facility in Port Lavaca, Texas, Trustmark National ...
... nutrition expert says, , WEDNESDAY, July 22 (HealthDay News) -- ... the kind of snack that matters, but who eats it. ... non-obese women, the healthy-weight women wanted less of the treat ... and non-obese women respond to high-energy, high-density snacks in different ...
... , , ... of the world,s leading research and advisory firms focusing on ... Bristol-Myers Squibb,s Orencia is low among rheumatoid arthritis agents. Rheumatologists ... necrosis factor-alpha (TNF-alpha) inhibitors across the top drivers of perception ...
Cached Medicine News:Health News:Vaxine Wins Line Honours With World's First Human Swine Flu Vaccine 2Health News:EPIX Pharmaceuticals, Inc. Assigns all Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors 2Health News:Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study 2Health News:Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study 3Health News:Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study 4Health News:Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study 5Health News:TrinityCare Senior Living Announces Extension of Financing for Trinity Shores Facility in Port Lavaca, Texas 2Health News:TrinityCare Senior Living Announces Extension of Financing for Trinity Shores Facility in Port Lavaca, Texas 3Health News:Eating Habits in the Obese May Echo Drug Addicts' Patterns 2Health News:Eating Habits in the Obese May Echo Drug Addicts' Patterns 3Health News:For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibb's Orencia 2Health News:For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibb's Orencia 3
FREEDOM® Memory Thumb Spica lets you make a custom splint in minutes. Immerese in 160 F water until pliable, and remove. Amazingly, it maintains its shape and is ready to be precisely, profession...
... Freedom® CMC ThumbFit™ reduces joint instability ... splint is remarkably comfortable and easy ... Kirby, OTR/L, CHT and Robert V. ... splint together in response to patients' ...
... offers thumb and wrist control in a ... Lightweight stays provide firm control at the ... contoured for proper positioning and fit. Ideal ... CMC joint arthritis, and following cast removal. ...
... Soft, foam-lined FoamWrap ThumWrap Splints offer support ... Ideal to relieve mild pain or strain ... activities. Choose either the rigid or the ... amount of support. Washable and breathable, the ...
Medicine Products: